With AstraZeneca’s big I-O combo reveal looming, investors get defensive

29th June 2017 Uncategorised 0

Eagerly awaited results from AstraZeneca’s phase 3 Mystic trial, a first-line immunotherapy combo study in lung cancer, should arrive any time now—and investors are getting prepared. The data could shift the I-O landscape and AZ’s fortunes, too.

More: With AstraZeneca’s big I-O combo reveal looming, investors get defensive
Source: fierce